LYEL · Lyell Immunopharma, Inc. · Metrics
$9.70
+0.90 (+10.23%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$215.65M
Shares
24.51M
Volume · Oct 20
158.62K
Avg daily vol (3M)
154.08K
LYEL metrics
76 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$9.70
Market cap
$215.65M
Price action
20 metricsPrice change (1W)
+6.4%
Price change (30D)
-19.5%
Price change (3M)
-31.9%
Price change (6M)
-64.6%
Price change (YTD)
-71.4%
Price change (1Y)
-46.7%
Trailing year
Price change (5Y)
—
52-week high
$38.60
52-week low
$7.51
Change from 52-week high
-77.2%
Change from 52-week low
+17.2%
Annualized volatility
79.5%
Annualized volatility (3M)
65.6%
Beta
1.4
RSI (14D)
39.5
Price vs SMA 50
-25.7%
Price vs SMA 200
-49.9%
Avg volume (3M)
153,564
Relative volume
1.4
Average dollar volume
$1.82M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
24.51M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
-189.6×
EV / EBITDA
—
EV / EBIT
—
P / sales
7,369.7×
reciprocal yield 0.0%
P / book
0.9
reciprocal yield 117.5%
FCF yield
-67.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-124.9%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
5,834.5×
reciprocal yield 0.0%
EV / revenue historical average (5Y)
5,834.5×
reciprocal yield 0.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-06
Profitability
9 metricsGross margin
—
Operating margin
-949,981.5%
Trailing 12 months
Net margin
-920,285.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$256.50M
Net income (TTM)
−$248.48M
Trailing 12 months
Diluted EPS (TTM)
$-12.65
FCF margin
-496,188.9%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-50.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$27,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+57.9%
Year over year · more shares
Revenue CAGR (3Y)
-92.5%
Revenue CAGR (5Y)
-65.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-106.3%
Return on assets
-79.9%
Debt / equity
0.0
Current ratio
5.4
EBITDA (TTM)
−$246.98M
Free cash flow (TTM)
−$133.97M
Quick ratio
5.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$204.10M
Latest balance sheet
Cash & equivalents
$72.98M
Total assets
$311.15M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$133.26M
Capital expenditures (TTM)
$711,000
R&D (TTM)
$156.50M
SG&A (TTM)
—
Stock compensation (TTM)
$39.63M
R&D / revenue
579,625.9%
Stock compensation / revenue
146,770.4%
Ownership (13F)
9 metrics13F filers
88
13F filer change QoQ
+12
Institutional ownership
52.0%
Conviction holders (share of 13F filers)
8.0%
Crowding (high-turnover and private-fund holders)
25.5%
Private-fund adviser ownership
25.0%
Active holders' share change QoQ
-8.5%
Holder tenure
7.5
Price vs estimated holder cost
-40.1%
Ownership (registered funds)
1 metricsIndex-fund ownership
6.2%
Short interest
3 metricsShort interest
5.2%
Latest settlement · 7.4 days to cover
Days to cover
7.4d
Short-squeeze score
67 / 100
Insider activity
2 metricsNet insider buying (90D)
−$214,668
Insider-sentiment score
25 / 100
Risk flags
1 metricsGoing concern
—